关注
Dirk Blom
Dirk Blom
在 uct.ac.za 的电子邮件经过验证
标题
引用次数
引用次数
年份
2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on …
RA Nishimura, CM Otto, RO Bonow, BA Carabello, JP Erwin III, ...
Circulation 129 (23), e521-e643, 2014
9566*2014
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
HC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, ...
The Lancet 394 (10193), 121-130, 2019
23712019
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events
MS Sabatine, RP Giugliano, SD Wiviott, FJ Raal, DJ Blom, J Robinson, ...
New England Journal of Medicine 372 (16), 1500-1509, 2015
16952015
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised …
FJ Raal, RD Santos, DJ Blom, AD Marais, MJ Charng, WC Cromwell, ...
The Lancet 375 (9719), 998-1006, 2010
10522010
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia
DJ Blom, T Hala, M Bolognese, MJ Lillestol, PD Toth, L Burgess, R Ceska, ...
New England Journal of Medicine 370 (19), 1809-1819, 2014
8862014
Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
FJ Raal, N Honarpour, DJ Blom, GK Hovingh, F Xu, R Scott, ...
The Lancet 385 (9965), 341-350, 2015
8522015
Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study
M Cuchel, EA Meagher, H du Toit Theron, DJ Blom, AD Marais, ...
The Lancet 381 (9860), 40-46, 2013
8202013
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia
JJP Kastelein, HN Ginsberg, G Langslet, GK Hovingh, R Ceska, R Dufour, ...
European heart journal 36 (43), 2996-3003, 2015
6392015
Risk factors for coronavirus disease 2019 (COVID-19) death in a population cohort study from the Western Cape Province, South Africa
Clinical Infectious Diseases 73 (7), e2005-e2015, 2021
5642021
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
HC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, ...
The Lancet 394 (10193), 131-138, 2019
5582019
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY …
CP Cannon, B Cariou, D Blom, JM McKenney, C Lorenzato, R Pordy, ...
European heart journal 36 (19), 1186-1194, 2015
4882015
Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events
MS Sabatine, RP Giugliano, SD Wiviott, FJ Raal, DJ Blom, J Robinson, ...
N Engl J Med 372 (16), 1500-1509, 2015
4702015
Volanesorsen and triglyceride levels in familial chylomicronemia syndrome
JL Witztum, D Gaudet, SD Freedman, VJ Alexander, A Digenio, ...
New England Journal of Medicine 381 (6), 531-542, 2019
4542019
Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy
FJ Raal, GJ Pilcher, VR Panz, HE van Deventer, BC Brice, DJ Blom, ...
Circulation 124 (20), 2202-2207, 2011
4342011
Reduction in lipoprotein (a) with PCSK9 monoclonal antibody evolocumab (AMG 145) a pooled analysis of more than 1,300 patients in 4 phase II trials
FJ Raal, RP Giugliano, MS Sabatine, MJ Koren, G Langslet, H Bays, ...
Journal of the American College of Cardiology 63 (13), 1278-1288, 2014
4182014
Triglyceride lowering with pemafibrate to reduce cardiovascular risk
A Das Pradhan, RJ Glynn, JC Fruchart, JG MacFadyen, ES Zaharris, ...
New England Journal of Medicine 387 (21), 1923-1934, 2022
3662022
Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset …
FJ Raal, GK Hovingh, D Blom, RD Santos, M Harada-Shiba, E Bruckert, ...
The lancet Diabetes & endocrinology 5 (4), 280-290, 2017
2502017
PCSK9 inhibition-mediated reduction in Lp (a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role [S]
FJ Raal, RP Giugliano, MS Sabatine, MJ Koren, D Blom, NG Seidah, ...
Journal of lipid research 57 (6), 1086-1096, 2016
2222016
Non-DNA binding, dominant-negative, human PPARγ mutations cause lipodystrophic insulin resistance
M Agostini, E Schoenmakers, C Mitchell, I Szatmari, D Savage, A Smith, ...
Cell metabolism 4 (4), 303-311, 2006
2172006
Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
AJ Vallejo-Vaz, CAT Stevens, ARM Lyons, KI Dharmayat, T Freiberger, ...
The Lancet 398 (10312), 1713-1725, 2021
1892021
系统目前无法执行此操作,请稍后再试。
文章 1–20